Cardiovascular Risk Markers Beyond LDL
Modern cardiovascular risk assessment goes beyond total and LDL cholesterol. ApoB (apolipoprotein B) counts atherogenic particles. Lipoprotein(a) is a genetic risk factor affecting roughly 20 percent of the population. Coronary Artery Calcium (CAC) score directly images atherosclerosis. hsCRP captures inflammation. ApoE genotype informs dietary and treatment decisions. Combined, these markers predict risk far better than lipid panels alone.
Viewpoints
Attia: Why ApoB is the critical cardiovascular risk marker
Peter Attia
“ApoB is a uniquely valuable cardiovascular risk biomarker because there is exactly one ApoB molecule per atherogenic lipoprotein particle, making it a precise count of circulating particles capable of infiltrating the artery wall and initiating atherosclerosis. Unlike HDL particles, which carry one to five copies of ApoA1 and are not atherogenic, ApoB-containing lipoproteins (LDL, VLDL, IDL, Lp(a)) are the particles that escape plasma clearance and drive plaque formation. The ratio of particle clearance by liver receptors versus artery wall invasion determines cardiovascular risk, underscoring why measuring ApoB concentration is more mechanistically informative than traditional lipid panels.”
Peter Attia: ApoB is the single best biomarker for cardiovascular risk
Rhonda Patrick
“ApoB (or LDL particle number) is the superior biomarker for cardiovascular disease risk, outperforming LDL cholesterol, non- HDL cholesterol, triglycerides, and HDL cholesterol. The three primary modifiable risk factors for heart disease are smoking, hypertension, and elevated ApoB — and despite dramatic reductions in smoking rates and effective pharmacological tools for controlling hypertension and ApoB, cardiovascular disease remains the leading cause of death, suggesting persistent lifestyle-driven contributions. This contrasts sharply with Alzheimer's disease, where neither the environmental triggers nor effective pharmacotherapies have been established.”
Key Moments
Attia: ApoB and LDL particle retention as the mechanistic driver of atherosclerosis
Peter Attia
“ApoB-containing particles, predominantly LDL, are causally implicated in atherosclerosis because they penetrate the endothelial barrier and enter the subendothelial space, where retained cholesterol undergoes oxidation and initiates plaque formation. Since roughly 95% of ApoB particles are LDL, measuring ApoB provides a reliable proxy for LDL particle concentration. The cholesterol and ApoB cannot be separated physiologically, making the causal debate between 'cholesterol' versus 'ApoB' a false dichotomy — both descriptors refer to the same pathogenic process. Key variables include the factors governing how long LDL is retained in the subendothelial space before its cholesterol cargo oxidizes.”
Rhonda Patrick: Primer on apolipoprotein classes and lipoprotein structure
Rhonda Patrick
“Lipoproteins are spherical particles whose surface proteins (apolipoproteins) determine their class and function: apoB-100 wraps LDL, IDL, and VLDL particles, while apoA wraps HDL particles. ApoB-48, found on chylomicrons, is less relevant to cardiovascular disease. Historical measurement of total cholesterol in the 1950s captured the combined cholesterol content across HDL, LDL, and VLDL, which was the first marker linked to cardiovascular risk before more refined fractionation was possible.”
Attia: ApoB as the key cardiovascular risk marker via lipoprotein biology
Peter Attia
“ApoB is now considered the most important marker for cardiovascular risk because cholesterol must enter the arterial wall to cause atherosclerosis, and it can only do so as a passenger inside lipoproteins. Since lipids are hydrophobic and cannot travel freely in aqueous plasma, evolution produced lipoproteins — complexes of lipids bound to structural proteins called apolipoproteins — as the transport vehicle. Every atherogenic particle carries one ApoB molecule, making ApoB count a direct proxy for the number of potentially artery- penetrating particles.”
Attia: Remnant lipoproteins as underappreciated cardiovascular risk drivers in insulin resistance
Peter Attia
“In insulin resistance, VLDLs and chylomicrons fail to offload their triglycerides, leading to elevated remnant lipoprotein particles that carry five to seven times more cholesterol per particle than LDL particles. These remnants are highly atherogenic because they are readily internalized into the artery wall and trigger inflammation, partly due to their apoE content. This explains why individuals with elevated triglycerides develop significant atherosclerosis not solely from excess LDL particles, but also from an underappreciated burden of cholesterol-rich remnant particles.”
Peter Attia: ApoB particle number is the primary driver of cardiovascular risk, and standard reference ranges are meaningless
Rhonda Patrick
“ApoB particle number is the first-order determinant of cardiovascular risk, with factors like cholesterol depletion of LDL particles being secondary because they are downstream of LDL residence time and clearance rate. Standard laboratory reference ranges for ApoB (e.g., <80 mg/dL labeled as 'excellent') are purely population-distribution artifacts — the 80 mg/dL cutoff simply reflects the 20th percentile of the population — and carry no inherent clinical meaning. Clinicians focused on longevity should editorialize beyond these ranges rather than treating them as therapeutic targets.”
Attia & Patrick: ApoE phenotype vs. genotype in Alzheimer's and cardiovascular risk
Rhonda Patrick
“ApoE expression level (phenotype) may matter more than ApoE genotype in determining Alzheimer's disease risk, paralleling how ApoB is used as a surrogate marker for LDL particle number in cardiovascular risk assessment. While ApoE 3/4 carriers face roughly a 2x increased Alzheimer's hazard ratio and 4/4 carriers face 10–20x increased risk, measurable ApoE protein levels could refine risk stratification beyond genotype alone, though no CLIA-approved clinical assay currently exists.”
Rhonda Patrick: LDL measurement methods and why ApoB is a superior risk marker
Rhonda Patrick
“The standard Friedewald equation used by most labs to estimate LDL cholesterol is frequently inaccurate, and direct LDL assays, while better, are still inferior predictors of cardiovascular risk compared to ApoB. Different LDL particle sizes and densities—particularly smaller, denser particles—also matter for atherogenicity, adding further complexity to relying on a single LDL-C number. ApoB captures the total number of atherogenic particles more accurately than any LDL cholesterol measurement method.”
Attia: ApoB as the superior cardiovascular risk predictor over LDL cholesterol
Rhonda Patrick
“Cardiovascular risk assessment has evolved from total cholesterol to LDL cholesterol, and now to apolipoprotein B (apoB), which counts the total concentration of all atherogenic particles capable of initiating and progressing atherosclerosis. ApoB measured in mg/dL represents the entire burden of particles that can cause plaque formation, making it a more precise predictor of cardiovascular risk than LDL-C. LDL cholesterol can be calculated via the Friedewald equation or measured directly, but neither captures particle number as comprehensively as apoB.”
Peter Attia: Why cholesterol is essential before discussing cardiovascular risk
Rhonda Patrick
“Cholesterol is not inherently harmful but is an essential molecule required for cellular membrane fluidity and as a precursor to critical steroid hormones including testosterone, estrogen, progesterone, and cortisol. Because cholesterol is hydrophobic and must travel through the water-based bloodstream, the body packages it into lipoproteins — a transport system whose components, particularly ApoB, are central to understanding cardiovascular disease risk.”
Attia & Guest: ApoB captures cardiovascular risk regardless of LDL particle size
Peter Attia
“ApoB is the primary marker of cardiovascular risk from LDL particles, capturing risk regardless of particle size. The common belief that large, 'fluffy' LDL particles are cardioprotective is incorrect — large LDL particles also cause conformational distortion of ApoB, impairing LDL receptor binding and thereby increasing atherogenic risk. This mechanism helps explain why familial hypercholesterolemia patients with large particles and defective LDL receptors still face elevated cardiovascular risk.”
Ronald Krauss: Ion mobility lipoprotein particle analysis as a refined cardiovascular risk tool
Rhonda Patrick
“Ion mobility analysis, which separates lipoprotein particles by size in air phase, represents the most refined method available for lipoprotein particle analysis and produces results consistent with prior methods. Once prohibitively expensive, its cost has dropped to near that of a standard cholesterol panel, removing previous barriers to clinical adoption. While standard lipid panels suffice for population screening, particle analysis becomes especially valuable for treatment decisions in borderline or high-risk patients.”
Powered by Symmerai — a living index of public discourse. Request early access →
Related concepts
Other relevant clips
334 - Cardiovascular disease, the number one killer: development, biomarkers, apoB, and more
Peter Attia
“…eatment of low HL cholesterol in the person you believe has cardiovascular risk is just like trigs lower APO b lower non-hdl cholesterol if you can't get an apob B I don't know what to if somebody has a high HDL cholesterol I don't know what blood test to tell”
334 - Cardiovascular disease, the number one killer: development, biomarkers, apoB, and more
Peter Attia
“…genes Tom as as you know my family history is riddled with cardiovascular disease and yet it doesn't come in the flavor of profound dyslipidemia right I have a normal LP little a I I never actually had a very elevated uh apob and in fact when I had that first”
Dr. Ben Bikman: How To Reverse Insulin Resistance Through Diet, Exercise, & Sleep
Rhonda Patrick
“cardiovascular risk than LDL is. So triglyceride to HDL ratio if it is if so you take your triglycerides which you're always going to get on a blood test and divide it by your HDL cholesterol which you're always going to get on a blood test. If that number is”
247 ‒ Preventing cardiovascular disease: the latest in imaging, blood pressure & metabolic health
Peter Attia
“…ething going on here that's not just standard plug-and-play risk factor stuff yeah which of course is your practice right I mean you get these really tough cases where it's not just oh you know the LDL is too high yeah it's it is my practice and unfortunately”
Dr. Ronald Krauss on LDL Cholesterol, Particle Size, Heart Disease & Atherogenic Dyslipidemia
Rhonda Patrick
“…food context. And the important regulators of heart disease risk from a dietary standpoint go way beyond the effects on blood cholesterol. And we have to think of a lot more complexity in the role of diet, not that cholesterol and lipoprotein effects aren't im”
380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats?
Peter Attia
“…would say that APOB and LDL are the only things that drive cardiovascular disease. blood pressure, um cardiovascular fitness, there's so many insulin sensitivity, inflammation, these things all matter. They all matter. We are just saying, and I'll give an exa”
Dr. Peter Attia on Mastering Longevity – Insights on Cancer Prevention, Heart Disease, and Aging
Rhonda Patrick
“…ould you do this you would follow people longitudinally for cardiovascular events and you would um do this in sort of a like a ACC cumulative in incidence graph so on the x- axxis you have time on the y- axis you have incidence of cardiovascular disease and yo”
380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats?
Peter Attia
“…olesterol is going down either genetically or through drugs cardiovascular mortality is going down. But why is it that in the MR study which in theory would be the most pure study every mill or every roughly 40 milligrams per deciliter reduction in LDL cholest”